12.56 USD
-0.42 (-3.24%)
12.74 USD
+0.18 (+1.43%)
We assign a fundamental rating of 3 out of 10 to OCUL. OCUL was compared to 192 industry peers in the Pharmaceuticals industry. OCUL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. OCUL is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
OCUL had negative earnings in the past year.
In the past year OCUL has reported a negative cash flow from operations.
In the past 5 years OCUL always reported negative net income.
In the past 5 years OCUL always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -60.77%, OCUL is not doing good in the industry: 66.15% of the companies in the same industry are doing better.
OCUL has a Return On Equity of -96.69%. This is in the lower half of the industry: OCUL underperforms 63.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -60.77% | ||
| ROE | -96.69% | ||
| ROIC | N/A |
ROA(3y)-40.62%
ROA(5y)-36.9%
ROE(3y)-116.88%
ROE(5y)-112.52%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
OCUL has a better Gross Margin (88.87%) than 90.63% of its industry peers.
OCUL's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for OCUL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.87% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.47%
GM growth 5Y15.21%
2. Health
2.1 Basic Checks
OCUL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for OCUL has been increased compared to 1 year ago.
Compared to 5 years ago, OCUL has more shares outstanding
OCUL has a better debt/assets ratio than last year.
2.2 Solvency
OCUL has an Altman-Z score of 5.90. This indicates that OCUL is financially healthy and has little risk of bankruptcy at the moment.
OCUL has a better Altman-Z score (5.90) than 76.04% of its industry peers.
A Debt/Equity ratio of 0.27 indicates that OCUL is not too dependend on debt financing.
OCUL has a Debt to Equity ratio of 0.27. This is comparable to the rest of the industry: OCUL outperforms 42.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.9 |
ROIC/WACCN/A
WACC9.87%
2.3 Liquidity
OCUL has a Current Ratio of 7.85. This indicates that OCUL is financially healthy and has no problem in meeting its short term obligations.
OCUL has a Current ratio of 7.85. This is in the better half of the industry: OCUL outperforms 72.92% of its industry peers.
A Quick Ratio of 7.78 indicates that OCUL has no problem at all paying its short term obligations.
The Quick ratio of OCUL (7.78) is better than 73.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.85 | ||
| Quick Ratio | 7.78 |
3. Growth
3.1 Past
OCUL shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.88%.
The Revenue has decreased by -9.21% in the past year.
The Revenue has been growing by 72.02% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)5.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-72.73%
Revenue 1Y (TTM)-9.21%
Revenue growth 3Y13.55%
Revenue growth 5Y72.02%
Sales Q2Q%-5.71%
3.2 Future
OCUL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.24% yearly.
OCUL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 55.40% yearly.
EPS Next Y-1.41%
EPS Next 2Y2.39%
EPS Next 3Y4.64%
EPS Next 5Y17.24%
Revenue Next Year-13.93%
Revenue Next 2Y-0.56%
Revenue Next 3Y11.68%
Revenue Next 5Y55.4%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for OCUL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OCUL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.39%
EPS Next 3Y4.64%
5. Dividend
5.1 Amount
OCUL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
12.56
-0.42 (-3.24%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners88.38%
Inst Owner Change19.84%
Ins Owners2.22%
Ins Owner Change-1.02%
Market Cap2.68B
Revenue(TTM)55.78M
Net Income(TTM)-249.67M
Analysts86.32
Price Target22.78 (81.37%)
Short Float %5.63%
Short Ratio3.81
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-4.72%
Min EPS beat(2)-7.83%
Max EPS beat(2)-1.62%
EPS beat(4)0
Avg EPS beat(4)-12.26%
Min EPS beat(4)-26.63%
Max EPS beat(4)-1.62%
EPS beat(8)1
Avg EPS beat(8)-40.57%
EPS beat(12)4
Avg EPS beat(12)-25.42%
EPS beat(16)6
Avg EPS beat(16)-13.78%
Revenue beat(2)0
Avg Revenue beat(2)-1.48%
Min Revenue beat(2)-2.51%
Max Revenue beat(2)-0.44%
Revenue beat(4)0
Avg Revenue beat(4)-10.82%
Min Revenue beat(4)-37.69%
Max Revenue beat(4)-0.44%
Revenue beat(8)1
Avg Revenue beat(8)-8.36%
Revenue beat(12)3
Avg Revenue beat(12)-6.11%
Revenue beat(16)3
Avg Revenue beat(16)-8.25%
PT rev (1m)6.35%
PT rev (3m)27.29%
EPS NQ rev (1m)-0.07%
EPS NQ rev (3m)15.52%
EPS NY rev (1m)0.07%
EPS NY rev (3m)4.4%
Revenue NQ rev (1m)1.35%
Revenue NQ rev (3m)-0.79%
Revenue NY rev (1m)-0.23%
Revenue NY rev (3m)0.14%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 47.97 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 10.36 | ||
| P/tB | 10.36 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.44
EYN/A
EPS(NY)-1.4
Fwd EYN/A
FCF(TTM)-0.94
FCFYN/A
OCF(TTM)-0.89
OCFYN/A
SpS0.26
BVpS1.21
TBVpS1.21
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -60.77% | ||
| ROE | -96.69% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.87% | ||
| FCFM | N/A |
ROA(3y)-40.62%
ROA(5y)-36.9%
ROE(3y)-116.88%
ROE(5y)-112.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.47%
GM growth 5Y15.21%
F-Score2
Asset Turnover0.14
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 232.75% | ||
| Cap/Sales | 16.8% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.85 | ||
| Quick Ratio | 7.78 | ||
| Altman-Z | 5.9 |
F-Score2
WACC9.87%
ROIC/WACCN/A
Cap/Depr(3y)138.13%
Cap/Depr(5y)98.78%
Cap/Sales(3y)6.55%
Cap/Sales(5y)5.44%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-72.73%
EPS Next Y-1.41%
EPS Next 2Y2.39%
EPS Next 3Y4.64%
EPS Next 5Y17.24%
Revenue 1Y (TTM)-9.21%
Revenue growth 3Y13.55%
Revenue growth 5Y72.02%
Sales Q2Q%-5.71%
Revenue Next Year-13.93%
Revenue Next 2Y-0.56%
Revenue Next 3Y11.68%
Revenue Next 5Y55.4%
EBIT growth 1Y-77.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-59.56%
EBIT Next 3Y-22.63%
EBIT Next 5Y19.4%
FCF growth 1Y-175.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-193.62%
OCF growth 3YN/A
OCF growth 5YN/A
OCULAR THERAPEUTIX INC / OCUL FAQ
What is the ChartMill fundamental rating of OCULAR THERAPEUTIX INC (OCUL) stock?
ChartMill assigns a fundamental rating of 3 / 10 to OCUL.
What is the valuation status for OCUL stock?
ChartMill assigns a valuation rating of 0 / 10 to OCULAR THERAPEUTIX INC (OCUL). This can be considered as Overvalued.
How profitable is OCULAR THERAPEUTIX INC (OCUL) stock?
OCULAR THERAPEUTIX INC (OCUL) has a profitability rating of 1 / 10.
What is the expected EPS growth for OCULAR THERAPEUTIX INC (OCUL) stock?
The Earnings per Share (EPS) of OCULAR THERAPEUTIX INC (OCUL) is expected to decline by -1.41% in the next year.